ArticleKidney medicine2025
The Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: New-onset IgA nephropathy (IgAN) and thrombotic microangiopathy (TMA) cases were reported after COVID-19 pandemic. This study investigated the prevalence and characteristics of IgAN-MA lesions in IgAN after the COVID-19 pandemic in China. Study Design: A cross-sectional study. Setting & Participants: A total of 22,123 biopsied patients, mainly in northern China from June 1, 2018, to May 31, 2024 were enrolled. Exposure: COVID-19 pandemic in China. Analytical Approach: Cochran-Armitage trend test was used to detect trends of IgAN and MA lesions after COVID-19 pandemic. Stage 1 represented no COVID-19 infection (including Stage 1A); Stage 2 represented possible COVID-19 infection and vaccination implemented; Stage 3 represented COVID-19 infection (including Stage 3A and Stage 3B). Multivariate logistic regression was used to analyze risk factors of MA lesions. Results: The proportion of IgAN in total biopsies and MA lesions in IgAN showed an increasing trend over time. In Stage 1, IgAN comprised 22.6% of total biopsies, significantly lower than the proportion in Stage 3 (24.5%; Limitations: Proportion based on patients in northern China, diagnosis from medical records without re-evaluation, lack of exact data on vaccination status and COVID-19 infection, lack of prognosis. Conclusions: COVID-19 may promote the proportion of IgAN in total biopsy and MA lesions in IgAN. Complement activation may play an important role in the development of IgAN and MA lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.